Crude Oil (CL)

L'intérêt à découvert pour Colgate-Palmolive donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Colgate-Palmolive. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Colgate-Palmolive (NYSE:CL) Stock, Rapport sur les intérêts à découvert

Colgate-Palmolive

Since its founding in 1806, Colgate-Palmolive has grown to become a leading player in the household and personal care arena. In addition to its namesake oral care line (which accounts for more than 40% of its total sales), the firm manufactures shampoos, shower gels, deodorants, and homecare products that are sold in over 200 countries. International sales account for about 70% of its total business, including approximately 45% from emerging regions. It also owns specialty pet food maker Hill's (around one fifth of sales), which primarily sells its products through veterinarians and specialty pet retailers.

Colgate-Palmolive Co

Core One Labs Inc

CHINA LIAONING DINGXU ECO by China Liaoning Dingxu Ecological Agriculture Development, Inc.

China Liaoning Dingxu Ecological Agriculture Development Inc

Clarus Corp

CHAVANT CAPITAL ACQUISITION CORP UNIT 1 COM & 1/3 WT EXP

CLARITAS PHARMACICLS INC by CLARITAS PHARMACEUTICALS INC.

Claritas Pharmaceuticals Inc

Core Laboratories Inc

CALBEE Inc

Columbia Financial Inc

CALIBER ENERGY INC by Caliber Energy, Inc.

Colombier Acquisition Corp. II Class A Ordinary Shares

Colombier Acquisition Corp II

Colombier Acquisition Corp. II Units, each consisting of one Class A ordinary share and one-third of one redeemable warrant

Colombier Acquisition Corp. II Warrants, each whole warrant exercisable for one Class A Ordinary Share at an exercise price of $11.50 per share

Colombier Acquisition Corp. II

Cellebrite DI Ltd

CORE LABORATORIES ORD

CHRISTINA LAKE CANNABIS by Christina Lake Cannabis Corp.

Christina Lake Cannabis Corp

CLICKS GROUP LTD S/ADR by Clicks Group Ltd

Clicks Group Ltd

CENTRAL CHINA SECS S/ADR by Central China Securities Co. Ltd.

Calcol Inc

Sinch AB

Cool Co Ltd

CEL Corp

Cell Source Inc

CapitaLand China Trust

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics Inc

Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50 per share

Direxion Daily Cloud Computing Bull 2X Shares

Chatham Lodging Trust (REIT) Common Shares of Beneficial Interest

Chatham Lodging Trust

Chatham Lodging Trust (REIT) 6.625% Series A Cumulative Redeemable Preferred Shares of Beneficial Interest

CLOUD3 VENTURES INC by CLOUD3 VENTURES INC

Cloud3 Ventures Inc

Celldex Therapeutics, Inc. - Common Stock

Celldex Therapeutics Inc

CELLDEX THERAPEUTICS ORD

Coles Group Ltd

COLES GROUP LTD UNSP/ADR by Coles Group Ltd.

AMUNDI IDX EMERGING ESG BROAD ETF

China Liberal Education Holdings Limited - Ordinary Shares

China Liberal Education Holdings Ltd

CONCRETE LEVELING SYS INC by Concrete Leveling Systems Inc.

Concrete Leveling Systems Inc

Cleveland-Cliffs Inc

Clearfield Inc

CLIFFORD MDERN IVING HLD by CLIFFORD MODERN LIVING HLDGS LTD.

CLEVELAND CLIFFS ORD

CLARITY METALS CORP by Clarity Metals Corp.

Clarity Metals Corp

Aris Mining Corp

CLEGHORN MINERALS ORD by Cleghorn Minerals

Cleghorn Minerals Ltd

CollPlant Biotechnologies Ltd. - Ordinary Shares

CollPlant Biotechnologies Ltd

CLEANGO INNOVATIONS INC by CleanGo Innovations Inc.

CleanGo Innovations Inc

CLEAN SEED CAP GROUP LTD by Clean Seed Capital Group Ltd

Clean Seed Capital Group Ltd

Cloud Nine Web3 Technologies Inc

HUTECH21 CO LTD NEW by Hutech21 Co., Ltd.

Hutech21 Co Ltd

Clean Harbors Inc

ClearDAO

CLST Holdings Inc

COLTENE HOLDING AG ORD by Coltene Holding AG

Coltene Holding AG

Tidal Trust II Veridien Climate Action ETF

Climate Real Impact Solutions III Acquisition

Energy Plug Technologies Corp

CORDLIFE GROUP LTD ORD by Cordlife Group Ltd

Cordlife Group Ltd

CLS HOLDINGS PLC ORD by CLS Holdings Plc.

CLS Holdings PLC

Click Holdings Ltd

CAPITALAND INVESTMENT LTD by Capitaland Investment Ltd.

CapitaLand Investment Ltd

UBS CLIMATE AWARE GLOBAL UCITS ETF

CLEAN EARTH ACQUISITIONS CORP RT

CLEAN EARTH ACQUISITIONS CORP UNIT 1 CL A COM & 1 RT 1/2 RED WT EXP

CLEAN EARTH ACQUISITIONS CORP RED WT EXP

Global X Funds Global X 1-3 Month T-Bill ETF

GLOBAL X 1-3 MONTH T-BILL USD AC ETF

ClearSign Technologies Corporation - Common Stock

ClearSign Technologies Corp

CLEARFORD WATER SYS INC by Clearford Water Systems, Inc.

Clearford Water Systems Inc

CLICKSTREAM CORP by ClickStream Corporation

ClickStream Corp

CITY OF LONDON INVST GRP by City of London Investment Group PLC

City of London Investment Group PLC

ProShares Long Online/Short Stores ETF

Clarke Inc

Calcitech Ltd

TWC ENTERPRISES LTD ORD by TWC Enterprises Ltd.

TWC Enterprises Ltd

CLAYTON & LAMBERT MFG CO by Clayton & Lambert Manufacturing Co.

CoLabs IntL Corp

CHALLENGER GOLD LIMITED by Challenger Gold Limited

Challenger Gold Ltd

COLLINS FOODS LTD NWMKT by Collins Foods Ltd Newmarket Qld

Collins Foods Ltd

BICO Group AB

COLLECTIVE METALS INC by COLLECTIVE METALS INC.

Collective Metals Inc

CELLNEX TELECOM UNSP/ADR by Cellnex Telecom SA

Cellnex Telecom SA

Cellectis S.A. - American Depositary Shares

Cellectis SA

CALLINEX MINES INC by Callinex Mines Inc.

Callinex Mines Inc

Cornerstone Strategic Value Fund, Inc. New Common Stock

Cornerstone Strategic Value Fund Inc

GUINNESS SUST ENERGY UCITS ETF GBX

Climb Global Solutions, Inc. - Common Stock

Climb Global Solutions Inc

CALIMA ENERGY LTD NEW by Calima Energy Ltd.

Calima Energy Ltd

CALGRO M3 HOLDINGS LTD by Calgro M3 Holdings Ltd.

Calgro M3 Holdings Ltd

Climeon AB

CANADIAN PREM SAND by Canadian Prem Sand Inc.

Canadian Premium Sand Inc

<h3 class="wp-block-heading">Chicago Atlantic</h3>
Chicago Atlantic Real Estate Finance, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REFI#NASDAQ">REFI</a>) will issue its earnings and supplemental financial information for the third quarter that ended Sept. 30, 2024, before the market opens on Thursday, Nov. 7.
The Chicago-based and cannabis-focused commercial mortgage real estate investment trust said a conference call and live audio webcast, both open for the general public, will be held later that day at 9:00 am Eastern Time.
The company&#8217;s portfolio performance remained strong with a total loan principal outstanding of $383.3 million across 31 investments, Chicago Atlantic said in August, on the heels of its second quarter <a href="https://www.benzinga.com/markets/cannabis/24/08/40228072/cannabis-reit-chicago-atlantic-nets-9-2m-in-strong-q2-citing-regulatory-tailwinds">financial results</a>. Also, the weighted average yield to maturity as of June 30, 2024, was approximately 18.7%, a slight decrease from 19.4% as of March 31, 2024, attributed to amendments in borrower performance and pricing structures.
Chicago Atlantic's shares traded 0.06% higher at $15.79 at the time of writing on Thursday morning.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/04/38168924/cannabis-reit-chicago-atlantic-closes-20m-facility-with-massachusetts-weed-co-that-plans-to-expa">Cannabis REIT Chicago Atlantic Closes $20M Facility With Massachusetts Weed Co. That Plans To Expand In These Key Markets</a>
<h3 class="wp-block-heading">NewLake Capital</h3>
NewLake Capital Partners, Inc. (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/NLCP#OTCQX">NLCP</a>) announced its plans Wednesday to host a conference call and report its financial results for the third quarter that ended Sept. 30, 2024, on Thursday, Nov. 14, 2024, at 11:00 am Eastern Time.
The company has emerged as a compelling player in the cannabis REIT sector. In May it announced its acquisition of a 58,500-square-foot industrial property in East Hartford, Connecticut. The company also said at the time that it had entered into a long-term triple net lease with an affiliate of Michigan-based C3 Industries Inc.
NewLake's shares traded 1.44% higher at $20.05 per share on Thursday morning.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/10/41314634/exclusive-how-to-raise-capital-in-cannabis-a-guide-to-debt-and-equity-for-avoiding-pitfalls-that">EXCLUSIVE: How To Raise Capital In Cannabis &#8211; A Guide To Debt And Equity For Avoiding Pitfalls That Sink Most Startups</a>
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
<h3 class="wp-block-heading">Cresco Labs</h3>
Cresco Labs Inc. (CSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#CSE">CL</a>) (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTCQX">CRLBF</a>) (FSE: 6CQ) will report financial results for the third quarter that ended Sept. 30, 2024 on Friday, Nov. 8, before the market opens.
Cresco, operator of Sunnyside dispensaries, said it will host a conference call and webcast to discuss its results and provide investors with key business highlights the same day.
The company&#8217;s second quarter report <a href="https://www.benzinga.com/markets/cannabis/24/08/40259646/cannabis-co-cresco-labs-q2-gross-profit-increases-over-9-yoy-reports-nearly-7-drop-in-revenue">published</a> in August demonstrated "the sustainability of the improvements we&#8217;ve made to the business over the past year with $184 million in revenue at a 29% Adjusted EBITDA margin,&#8221; said CEO Charles Bachtell.
Cresco Labs made its debut in Chicago in 2013 when Illinois passed the Compassionate Use of Medical Cannabis Act. "The company&#8217;s goal and that of its management team has been to help normalize and professionalize this industry," Bachtell told the crowd gathered at the <a href="https://www.benzinga.com/events/cannabis-conference/">Benzinga Cannabis Capital Conference</a> <a href="https://www.benzinga.com/markets/cannabis/24/10/41258536/exclusive-cannabis-companies-must-get-more-juice-from-the-same-squeeze-says-cresco-labs-ceo-as-c">in Chicago in early October.</a>
A September note from Zuanic &amp; Associates rated Cresco as "Overweight" among the top five multi-state operators (MSOs) in the U.S. According to Zuanic, Cresco's financial performance in Q2 2024 underscores its efficiency-focused strategy, adding that key opportunities lie in Cresco's footprint in <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40779975/is-cresco-labs-an-overlooked-cannabis-stock-market-potential-in-ohio-florida-pennsy">states like Ohio, Florida and Pennsylvania.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/10/41365990/cannabis-debt-looms-for-these-weed-giants-heres-how-some-tackled-their-financial-challenges">Cannabis Debt Looms For These Weed Giants: Here&#8217;s How Some Tackled Their Financial Challenges</a></li>
</ul>

Cannabis

Earnings

News

REIT

Real Estate

CRLBF

CSE:CL

NLCP

REFI

Cannabis Earnings Update: Marijuana Lenders And Top Operator To Report Results, Here's What Investors Need To Know

Throughout the last three months, 16 analysts have evaluated Colgate-Palmolive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>), offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Colgate-Palmolive, presenting an average target of $106.81, a high estimate of $122.00, and a low estimate of $91.00. This upward trend is apparent, with the current average reflecting a 4.56% increase from the previous average price target of $102.15.
<img src="https://www.benzinga.com/files/images/story/2024/1728655233_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Colgate-Palmolive. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrea Teixeira</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$114.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Korinne Wolfmeyer</td>
<td>Piper Sandler</td>
<td>Announces</td>
<td>Overweight</td>
<td>$121.00</td>
<td>-</td>
</tr>
<tr>
<td>Chris Carey</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Underweight</td>
<td>$100.00</td>
<td>-</td>
</tr>
<tr>
<td>Steve Powers</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$109.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Peter Grom</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$122.00</td>
<td>$119.00</td>
</tr>
<tr>
<td>Robert Moskow</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$115.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Callum Elliott</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$103.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Steve Powers</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$107.00</td>
<td>$104.00</td>
</tr>
<tr>
<td>Dara Mohsenian</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$111.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>Lauren Lieberman</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$96.00</td>
<td>$91.00</td>
</tr>
<tr>
<td>Kaumil Gajrawala</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$95.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>Robert Moskow</td>
<td>TD Cowen</td>
<td>Announces</td>
<td>Buy</td>
<td>$110.00</td>
<td>-</td>
</tr>
<tr>
<td>Mark Astrachan</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$105.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Lauren Lieberman</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$91.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Robert Ottenstein</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$106.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Steve Powers</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$104.00</td>
<td>$98.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Colgate-Palmolive. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Colgate-Palmolive compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Colgate-Palmolive's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Colgate-Palmolive's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Colgate-Palmolive analyst ratings.</a>
<h2>Delving into Colgate-Palmolive's Background</h2>
Since its founding in 1806, Colgate-Palmolive has grown to become a leading player in the household and personal care arena. In addition to its namesake oral care line (which accounts for more than 40% of its total sales), the firm manufactures shampoos, shower gels, deodorants, and homecare products that are sold in over 200 countries. International sales account for about 70% of its total business, including approximately 45% from emerging regions. It also owns specialty pet food maker Hill's (around one fifth of sales), which primarily sells its products through veterinarians and specialty pet retailers.
<h3>Colgate-Palmolive's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Colgate-Palmolive's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 4.89%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Staples sector.
Net Margin: Colgate-Palmolive's net margin is impressive, surpassing industry averages. With a net margin of 14.45%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 414.16%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Colgate-Palmolive's ROA stands out, surpassing industry averages. With an impressive ROA of 4.42%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Colgate-Palmolive's debt-to-equity ratio stands notably higher than the industry average, reaching 70.54. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

A Glimpse Into The Expert Outlook On Colgate-Palmolive Through 16 Analysts

JP Morgan analyst Andrea Teixeira maintains Colgate-Palmolive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) with a Overweight and raises the price target from $113 to $114.

Price Target

JP Morgan Maintains Overweight on Colgate-Palmolive, Raises Price Target to $114

Another <a href="https://www.benzinga.com/events/cannabis-conference/">Benzinga Cannabis Capital Conference</a> is in the books. The two-day event took place in Chicago this week, gathering a slew of top cannabis entrepreneurs, executives, politicians and industry stakeholders. That said, let's scroll through latest executive changes in cannabis.
<h3 class="wp-block-heading">The U.S. Hemp Roundtable Taps Two Prominent Executives In Hemp Beverage Space Into Its Ranks</h3>
The U.S. Hemp Roundtable made headlines in early September as its board of directors <a href="https://hempsupporter.com/news/u-s-hemp-roundtable-makes-big-splash-into-hemp-beverage-space-with-election-of-two-prominent-executives/">welcomed</a> two distinguished leaders from the hemp beverage sector to its officer ranks. Art Massolo, vice president of business development at Cycling Frog, agreed to serve as the new executive vice president, while Aaron Nosbisch, founder of BRĒZ, assumed the role of vice president of E-Commerce.
"Beverages represent the fastest-growing segment of the hemp industry, and the Roundtable is blessed to have two of the industry's most prominent leaders join us as Vice Presidents," Jonathan Miller, the Roundtable's general counsel, said.&nbsp;
<h3 class="wp-block-heading">Cannabis Leadership Shake-Ups In New York</h3>
New York's chief equity officer at the state Office of Cannabis Management, Damian Fagon, has formally resigned, effective November 27. He was previously cleared of any wrongdoing in an inspector general investigation that found no basis for allegations of retaliation against a cannabis company, <a href="https://www.greenmarketreport.com/new-york-cannabis-chief-equity-officer-resigns-following-exoneration-from-retaliation-allegations/">reported</a> Green Market Report.
Fagon was placed on administrative leave this spring after cannabis processor Jenny Argie filed a lawsuit claiming that he had retaliated against her business by advocating for a recall of her products following her criticism of the OCM to Syracuse.com last year. That lawsuit was dismissed in July.
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
In the meantime, New York Cannabis Control Board recently got a new member in September. Crystal J. Rodriguez-Dabney was appointed to serve on the board as per a decision from state Assembly Speaker Carl Heastie, following a recommendation from Majority Leader Crystal Peoples-Stokes, GMR <a href="https://www.greenmarketreport.com/dei-attorney-named-to-new-york-cannabis-regulatory-board/">reported</a>.
"This is a wonderful opportunity and an ever bigger responsibility as we seek to ensure equity in the entire process. Looking forward to working with the (Office of Cannabis Management)&nbsp;and learning the ins and outs of this legendary legislation," Rodriguez-Dabney, who succeeded former member Adam Perry, wrote in a <a href="https://www.linkedin.com/feed/update/urn:li:activity:7244661542661550081/">social media post.</a>
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/10/41261875/exclusive-why-loyalty-programs-not-discounts-are-the-future-of-cannabis-retail">EXCLUSIVE: Why Loyalty Programs, Not Discounts, Are The Future Of Cannabis Retail</a>
<h3 class="wp-block-heading">Legal Saga Around Massachusetts Regulatory Body Continues</h3>
Former chair of Cannabis Control Commission of Massachusetts Shannon O'Brien lost her legal battle with State Treasurer Deborah Goldberg resulting in <a href="https://www.benzinga.com/markets/cannabis/24/09/40797285/massachusetts-cannabis-chief-shannon-obrien-loses-job-after-year-long-suspension-and-costly-lega">her being fired last month.</a> O'Brien was originally appointed to serve a five-year term in 2022 and has denied the misconduct allegations. Goldberg suspended O'Brien last September accusing her of making "racially, ethnically and culturally insensitive statements."
Goldberg <a href="https://masscannabiscontrol.com/2024/09/cannabis-control-commissioner-bruce-stebbins-named-acting-chair-by-state-treasurer-deborah-b-goldberg/">named</a> Bruce Stebbins acting chair of the regulatory body, succeeding O'Brien who now plans to appeal her firing as the chairwoman of CCC to the Supreme Judicial Court, <a href="https://www.thecannabist.co/2024/09/16/ousted-shannon-obrien-vows-legal-battle-over-pot-board-firing/136685/">reported</a> The Cannabist.
<h3 class="wp-block-heading">Cannabis Board Changes</h3>
Aurora Cannabis Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ACB#TSX">ACB</a>) CEO Miguel Martin agreed recently to serve in the additional role of executive chairman. Outgoing chairman Ron Funk will serve as lead independent director going forward.
IM Cannabis Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMCC#NASDAQ">IMCC</a>) (CSE:<a class="ticker" href="https://www.benzinga.com/stock/IMCC#CSE">IMCC</a>), a leading medical cannabis company with operations in Israel and Germany, announced last month that Shmulik Arbel has been appointed to its board of directors effective Sept. 9.
Rubicon Organics Inc. (TSXV:<a class="ticker" href="https://www.benzinga.com/stock/ROMJ#TSXV">ROMJ</a>) (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/ROMJF#OTCQX">ROMJF</a>) welcomed Jesse McConnell to its board of directors in early September, after receipt of security clearance from Health Canada.
Canopy Growth Corporation's (TSX:<a class="ticker" href="https://www.benzinga.com/stock/WEED#TSX">WEED</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) shareholders each of the directors listed as a nominee at their annual general meeting of shareholders held on Sept.24, including David Klein, Willy Kruh, David Lazzarato, Luc Mongeau and Theresa Yanofsky.
TILT Holdings Inc.'s (NEO: TILT) (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/TLLTF#OTCQX">TLLTF</a>) Adam Draizin opted to step down from the company's board of directors effective Oct. 1. Marshall P. Horowitz was appointed to the board as Draizin's replacement.
Flora Growth Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLGC#NASDAQ">FLGC</a>) (FSE: 7301) named Harold Wolkin as an independent director on its board of directors last month. In this role, Wolkin also agreed to serve as a member of each of the company&#8217;s committees, including as chair of the audit committee. Separately, Clifford Starke, the company's CEO, was recently tapped as a member of the board of directors of HoshiCap, a subsidiary of Hoshi International which has a cannabis cultivation facility in Portugal.
<h3 class="wp-block-heading">Other Appointments And Resignations</h3>
CANNAVIGIA, a Swiss tech start-up focused on innovative cannabis solutions via software and consulting, announced recently that founder and CEO Luc Richner opted into the role of chief strategy Officer, while Timo Bongartz, chief commercial officer, agreed to replace Richner as CEO.
Nextleaf Solutions Ltd. (CSE:<a class="ticker" href="https://www.benzinga.com/stock/OILS#CSE">OILS</a>) (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/OILFF#OTCQB">OILFF</a>) named Emma Andrews as its CEO. Andrews has acted as the Company&#8217;s Interim CEO since Sept 8, 2023, and has been with the company for six years, previously as the director of marketing.
Endexx Corporation (OTC:<a class="ticker" href="https://www.benzinga.com/stock/EDXC#OTC">EDXC</a>) appointed Doug Williams, CPA, as fractional CFO through his consulting firm, Alexander &amp; Williams PLLC in early October.
AYR Wellness Inc. (CSE:<a class="ticker" href="https://www.benzinga.com/stock/AYR#CSE">AYR</a>) (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/AYRWF#OTCQX">AYRWF</a>) President and CEO David Goubert stepped down from his role in the company last month. The board has approved the appointment of Steven M. Cohen as interim CEO.
Cresco Labs Inc. (CSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#CSE">CL</a>) (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTCQX">CRLBF</a>) (FSE: 6CQ) announced last month that Dennis Olis, CEO, retire after a planned transition to Sharon Schuler, a financial and strategy executive.
SNDL Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDL#NASDAQ">SNDL</a>) announced in early September that after two decades of leadership and innovation in the liquor industry, Taranvir (Tank) Vander, president of the liquor division, retired from the company to pursue new opportunities.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/10/41262813/exclusive-poking-the-bear-as-floridas-contentious-cannabis-legalization-vote-looms">EXCLUSIVE: &#8216;Poking The Bear&#8217; As Florida&#8217;s Contentious Cannabis Legalization Vote Looms</a></li>
</ul>

Entrepreneurship

Movers & Shakers

AYRWF

CSE:AYR

CSE:IMCC

CSE:OILS

EDXC

FLGC

IMCC

OILFF

ROMJF

SNDL

TILT

TLLTF

TSX:ACB

TSX:ROMJ

TSX:WEED

TSXV:ROMJ

WEED

The Ever-Evolving Cannabis Industry: These Are Latest Leadership Changes You Should Know About

Finding a balance between getting more scale, but still being productive and having high margins in the current landscape in the cannabis industry, is a "daily challenge." That's according to Charlie Bachtell, CEO and co-founder of Cresco Labs Inc (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTCQX">CRLBF</a>), a company running over 70 cannabis retail locations nationwide.
It involves continually adapting to new challenges, strategies, and emerging trends across a company's operations. "You&#8217;re constantly trying to forecast where this industry is headed and at the same time, understand the industry that you&#8217;re in today," Bachtell said during a fireside chat with Jesse Redmond, head of cannabis at Water Tower Research LLC, at the <a href="https://www.benzinga.com/events/cannabis-conference/">Benzinga Cannabis Capital Conference</a> on Wednesday, in Chicago.
He added that running a cannabis business over the past decade depended heavily on how well organizations have been able to speculate about how fast and in what direction the nascent market would go.
The cannabis industry is unique among other "super fast-moving" emerging industries due to challenges to access capital and the impact of 280e on taxation.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/cannabis-conference/"><img loading="lazy" decoding="async" width="970" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/09132606/ccc-oct-24-banner__1_-20.gif" alt="" class="wp-image-588186" /></a></figure>
"Not only are you fighting this fight with one and a half hands tied behind your back, but then you are also expected to get profitable too," Bachtell said, adding it&#8217;s a constant evaluation and balancing growth while maintaining margins.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/10/41250811/exclusive-were-finally-on-the-cusp-of-something-big-verano-ceo-sees-cannabis-rescheduling-as-gam">EXCLUSIVE: &#8216;We&#8217;re Finally On The Cusp Of Something Big&#8217; — Verano CEO Sees Cannabis Rescheduling As Game-Changer</a>
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
<h3 class="wp-block-heading">A Success Story</h3>
Cresco Labs made its debut in Chicago in 2013 when Illinois passed the Compassionate Use of Medical Cannabis Act. &#8220;The company's goal and that of its management team has been to help normalize and professionalize this industry,&#8221; Bachtell said.
Following nascent years of getting the first buildings built and becoming operational, the company has been scaling ever since. After attempting and failing to merge with Columbia Care Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CCHWF#OTC">CCHWF</a>) &#8211; now known as The Cannabist Company Holdings Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBSTF#OTC">CBSTF</a>) &#8211; 2023 came as "the year of the core."
"After attempting the large MMA deal, we really needed to focus on our core business and making sure that we got Cresco Labs as tight and as sound and as efficient as we possibly could, which would then best prepare us for growth in the years ahead," he said.
Year-to-date, Cresco has positioned itself to capitalize on catalysts, such as potential shifts to recreational markets in states where it already operates as a medical cannabis provider, including Ohio, Florida, and Pennsylvania, where the regulatory landscape continues to evolve.
It is important to figure out "ways to get smarter… leaner and get more juice from the same squeeze," Bachtell said. The primary focus should be to develop "skill sets that are transportable and transferable from state to state in the limited ability that you have to do it."
<h3 class="wp-block-heading">Seizing Cannabis Regulatory Shifts</h3>
That said, Bachtell is optimistic Florida's <a href="https://www.benzinga.com/markets/cannabis/24/10/41250277/miami-herald-endorses-florida-cannabis-legalization-highlights-failed-drug-war-revenue-potential">Amendment 3</a> would allow the company to go recreational in the state. Former President Donald Trump&#8216;s support has increased the likelihood of the success, he added.
"The two leaders of the main political parties in the United States both being in favor of legalization is something that we should not miss, and recognize the importance of it," Bachtell said.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/10/41241003/exclusive-cannabis-rescheduling-is-not-cure-all-for-industry-problems-experts-explain-how-tax-ta">EXCLUSIVE: Cannabis Rescheduling Is Not Cure-All For Industry Problems: Experts Explain How Tax Tactics Could Hurt Marijuana Businesses In Long Run</a></li>
</ul>
Charlie Bachtell, CEO and co-founder of Cresco Labs, speaks at the Benzinga Cannabis Capital Conference on Wednesday. Photo by Wendy Davis.

Events

Exclusives

Interview

THE CANNABIST CO HLDG by THE CANNABIST COMPANY HOLDINGS INC.

CBSTF

CCHWF

EXCLUSIVE: Cannabis Companies Must 'Get More Juice From The Same Squeeze,' Says Cresco Labs CEO As Challenges Persist

Looking into the current session, Colgate-Palmolive Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) shares are trading at $102.50, after a 1.20% decrease. Over the past month, the stock fell by 2.73%, but over the past year, it actually went up by 44.73%. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2024/1727376314_0.png" alt="Past Year Chart" />

<h3>A Look at Colgate-Palmolive P/E Relative to Its Competitors</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of the 45.41 in the Household Products industry, Colgate-Palmolive Inc. has a lower P/E ratio of 30.25. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1727376314_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

Price Over Earnings Overview: Colgate-Palmolive

Investors with a lot of money to spend have taken a bullish stance on Colgate-Palmolive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with CL, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 10 options trades for Colgate-Palmolive.
This isn't normal.
The overall sentiment of these big-money traders is split between 90% bullish and 10%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $32,560, and 9, calls, for a total amount of $794,180.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $97.5 to $110.0 for Colgate-Palmolive over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Colgate-Palmolive's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Colgate-Palmolive's significant trades, within a strike price range of $97.5 to $110.0, over the past month.
<h3>Colgate-Palmolive Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727283650_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/11/24</td>
<td>$5.5</td>
<td>$5.4</td>
<td>$5.5</td>
<td>$99.00</td>
<td>$110.0K</td>
<td style="text-align: right;">1</td>
<td>1.4K</td>
</tr>
<tr>
<td>CL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/11/24</td>
<td>$5.5</td>
<td>$5.2</td>
<td>$5.5</td>
<td>$99.00</td>
<td>$110.0K</td>
<td style="text-align: right;">1</td>
<td>1.0K</td>
</tr>
<tr>
<td>CL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/11/24</td>
<td>$5.5</td>
<td>$5.4</td>
<td>$5.5</td>
<td>$99.00</td>
<td>$109.8K</td>
<td style="text-align: right;">1</td>
<td>1.6K</td>
</tr>
<tr>
<td>CL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/11/24</td>
<td>$5.5</td>
<td>$5.4</td>
<td>$5.5</td>
<td>$99.00</td>
<td>$109.8K</td>
<td style="text-align: right;">1</td>
<td>1.2K</td>
</tr>
<tr>
<td>CL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/11/24</td>
<td>$5.4</td>
<td>$5.2</td>
<td>$5.4</td>
<td>$99.00</td>
<td>$107.8K</td>
<td style="text-align: right;">1</td>
<td>600</td>
</tr>
</tbody>
</table>

<h3>About Colgate-Palmolive</h3>
Since its founding in 1806, Colgate-Palmolive has grown to become a leading player in the household and personal care arena. In addition to its namesake oral care line (which accounts for more than 40% of its total sales), the firm manufactures shampoos, shower gels, deodorants, and homecare products that are sold in over 200 countries. International sales account for about 70% of its total business, including approximately 45% from emerging regions. It also owns specialty pet food maker Hill's (around one fifth of sales), which primarily sells its products through veterinarians and specialty pet retailers.
In light of the recent options history for Colgate-Palmolive, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Colgate-Palmolive's Current Market Status</h3>
<ul>
<li>Trading volume stands at 845,127, with CL's price down by -0.07%, positioned at $103.72.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 30 days.</li>
</ul>
<h3>Expert Opinions on Colgate-Palmolive</h3>
4 market experts have recently issued ratings for this stock, with a consensus target price of $113.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from Wells Fargo lowers its rating to Underweight with a new price target of $100. 
&#x2A; An analyst from UBS has decided to maintain their Buy rating on Colgate-Palmolive, which currently sits at a price target of $122. 
&#x2A; An analyst from Piper Sandler has revised its rating downward to Overweight, adjusting the price target to $121. 
&#x2A; Reflecting concerns, an analyst from Deutsche Bank lowers its rating to Hold with a new price target of $109.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Colgate-Palmolive with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Check Out What Whales Are Doing With Colgate-Palmolive

Piper Sandler analyst Korinne Wolfmeyer initiates coverage on Colgate-Palmolive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) with a Overweight rating and announces Price Target of $121.

Initiation

Piper Sandler Initiates Coverage On Colgate-Palmolive with Overweight Rating, Announces Price Target of $121

Deep-pocketed investors have adopted a bullish approach towards Colgate-Palmolive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in CL usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for Colgate-Palmolive. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 37% leaning bullish and 37% bearish. Among these notable options, 2 are puts, totaling $61,200, and 6 are calls, amounting to $228,304.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $95.0 and $105.0 for Colgate-Palmolive, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Colgate-Palmolive options trades today is 881.17 with a total volume of 1,167.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Colgate-Palmolive's big money trades within a strike price range of $95.0 to $105.0 over the last 30 days.
<h3>Colgate-Palmolive Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727111761_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$8.5</td>
<td>$8.3</td>
<td>$8.5</td>
<td>$97.50</td>
<td>$55.2K</td>
<td>520</td>
<td style="text-align: right;">100</td>
</tr>
<tr>
<td>CL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$0.95</td>
<td>$0.9</td>
<td>$0.95</td>
<td>$105.00</td>
<td>$48.0K</td>
<td>2.6K</td>
<td style="text-align: right;">530</td>
</tr>
<tr>
<td>CL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$7.5</td>
<td>$7.2</td>
<td>$7.48</td>
<td>$97.50</td>
<td>$37.4K</td>
<td>612</td>
<td style="text-align: right;">92</td>
</tr>
<tr>
<td>CL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$4.6</td>
<td>$4.5</td>
<td>$4.5</td>
<td>$95.00</td>
<td>$34.2K</td>
<td>250</td>
<td style="text-align: right;">76</td>
</tr>
<tr>
<td>CL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/27/24</td>
<td>$4.1</td>
<td>$4.0</td>
<td>$4.0</td>
<td>$100.00</td>
<td>$30.8K</td>
<td>195</td>
<td style="text-align: right;">192</td>
</tr>
</tbody>
</table>

<h3>About Colgate-Palmolive</h3>
Since its founding in 1806, Colgate-Palmolive has grown to become a leading player in the household and personal care arena. In addition to its namesake oral care line (which accounts for more than 40% of its total sales), the firm manufactures shampoos, shower gels, deodorants, and homecare products that are sold in over 200 countries. International sales account for about 70% of its total business, including approximately 45% from emerging regions. It also owns specialty pet food maker Hill's (around one fifth of sales), which primarily sells its products through veterinarians and specialty pet retailers.
In light of the recent options history for Colgate-Palmolive, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of Colgate-Palmolive</h3>
<ul>
<li>Trading volume stands at 1,380,483, with CL's price up by 0.51%, positioned at $103.59.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 32 days.</li>
</ul>
<h3>Expert Opinions on Colgate-Palmolive</h3>
3 market experts have recently issued ratings for this stock, with a consensus target price of $110.33333333333333.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Wells Fargo has revised its rating downward to Underweight, adjusting the price target to $100. 
&#x2A; An analyst from UBS has decided to maintain their Buy rating on Colgate-Palmolive, which currently sits at a price target of $122. 
&#x2A; An analyst from Deutsche Bank has revised its rating downward to Hold, adjusting the price target to $109. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Colgate-Palmolive, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Unpacking the Latest Options Trading Trends in Colgate-Palmolive

Wells Fargo analyst Chris Carey downgrades Colgate-Palmolive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) from Equal-Weight to Underweight and announces $100 price target.

Downgrades

Wells Fargo Downgrades Colgate-Palmolive to Underweight, Announces $100 Price Target

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page.</a>
<ul>
<li>Ascendiant Capital raised the price target for Pro-Dex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) from $28 to $30. Ascendiant Capital analyst Edward Woo maintained a Buy rating. Pro-Dex shares gained 4.2% to close at $23.28 on Friday. <a href="https://www.benzinga.com/quote/PDEX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. boosted the price target for Summit Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) from $16 to $30. HC Wainwright &amp; Co. analyst Mitchell Kapoor maintained a Buy rating. Summit Therapeutics shares fell 1.8% to close at $12.27 on Friday. <a href="https://www.benzinga.com/quote/MEI/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JP Morgan raised United States Steel Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>) price target from $40 to $42. JP Morgan analyst Bill Peterson upgraded the stock from Neutral to Overweight. United States Steel shares gained 4.3% to close at $31.27 on Friday. <a href="https://www.benzinga.com/quote/SMMT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Morgan Stanley raised Costco Wholesale Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) price target from $855 to $950. Morgan Stanley analyst Simeon Gutman maintained an Overweight rating. Costco shares fell 1.1% to close at $876.68 on Friday. <a href="https://www.benzinga.com/quote/COST/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wedbush boosted the price target for LGI Homes, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGIH#NASDAQ">LGIH</a>) from $97 to $125. Wedbush analyst Jay McCanless upgraded the stock from Underperform to Neutral. LGI Homes shares rose 0.8% to close at $104.80 on Friday. <a href="https://www.benzinga.com/quote/LGIH/analyst-ratings">See how other analysts view this stock.</a></li>
<li>BTIG increased Roblox Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) price target from $47 to $51. BTIG analyst Clark Lampen maintained a Buy rating. Roblox shares fell 0.2% to close at $43.64 on Friday. <a href="https://www.benzinga.com/quote/RBLX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities raised JetBlue Airways Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBLU#NASDAQ">JBLU</a>) price target from $3 to $6. B of A Securities analyst Andrew Didora upgraded the stock from Underperform to Neutral. JetBlue shares fell 1.7% to close at $5.30 on Friday. S<a href="https://www.benzinga.com/quote/JBLU/analyst-ratings">ee how other analysts view this stock.</a></li>
<li>Deutsche Bank increased the price target for Colgate-Palmolive Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) from $107 to $109. Deutsche Bank analyst Steve Powers downgraded the stock from Buy to Hold. Colgate-Palmolive shares fell 0.6% to close at $107.86 on Friday. See how other analysts view this stock.</li>
<li>JP Morgan boosted Nucor Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) price target from $170 to $174. JP Morgan analyst Bill Peterson upgraded the stock from Neutral to Overweight. Nucor shares fell 0.6% to close at $138.79 on Friday. <a href="https://www.benzinga.com/quote/NUE/analyst-ratings">See how other analysts view this stock.</a></li>
<li>BMO Capital boosted Starbucks Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) price target from $100 to $110. BMO Capital analyst Andrew Strelzik maintained an Outperform rating. Starbucks shares fell 0.5% to close at $91.15 on Friday. <a href="https://www.benzinga.com/quote/SBUX/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying SBUX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="506" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/09085953/image-70-1024x506.png" alt="" class="wp-image-537416" style="width:621px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/09085953/image-70-1024x506.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/09085953/image-70-300x148.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/09085953/image-70-768x380.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/09085953/image-70.png 1368w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>

Comments

Colgate-Palmolive

Intérêt court

Colgate-Palmolive (NYSE:CL) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL